Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

9.660 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics
Via Benzinga
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
Via Benzinga
Analyst Expectations For Stoke Therapeutics's Future
Via Benzinga
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
Via Benzinga
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
What's Going On With Stoke Therapeutics Stock Tuesday?
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a... 
Via Benzinga
Crude Oil Moves Lower; TD SYNNEX Earnings Top Estimates
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81... 
Via Benzinga
Dow Gains 100 Points; McCormick Posts Upbeat Results
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Tuesday. The Dow traded up 0.08% to 39,346.40 while the NASDAQ rose 0.39% to 16,448.92. The S&P 500 also... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients
New data from Stoke Therapeutics' STK-001 studies reveal significant reductions in seizures and cognitive improvements in children with Dravet syndrome. STK-001 demonstrates promise as a well-tolerated... 
Via Benzinga
Why Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?
NeuBase Therapeutics stock is down on Tuesday as NBSE investors react to details concerning an upcoming special shareholder meeting. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Check-Cap (CHEK) Stock Up 44% Today?
Check-Cap stock is up on Tuesday with heavy trading as CHEK investors react to news of a business combination with Nobul AI. 
Via InvestorPlace
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001 
Via Benzinga
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
Stoke Therapeutics stock is up on Tuesday as STOK shares see heavy trading alongside recent positive clinical trial data. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning! 
Via InvestorPlace
STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023
STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.